Ticker > Company >

Torrent Pharma share price

Torrent Pharmaceuticals Ltd.

NSE: TORNTPHARM BSE: 500420 SECTOR: Pharmaceuticals & Drugs  1.86 L   298   28

4256.85
+26.75 (0.63%)
BSE: Today, 09:09 AM

Price Summary

Today's High

₹ 4256.85

Today's Low

₹ 4256.85

52 Week High

₹ 4479.7

52 Week Low

₹ 3101

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

144071.15 Cr.

Enterprise Value

146508.25 Cr.

No. of Shares

33.84 Cr.

P/E

65.52

P/B

15.95

Face Value

₹ 5

Div. Yield

0.76 %

Book Value (TTM)

₹  266.87

CASH

109.74 Cr.

DEBT

2546.84 Cr.

Promoter Holding

68.31 %

EPS (TTM)

₹  64.97

Sales Growth

13.47%

ROE

26.18 %

ROCE

27.82%

Profit Growth

39.13 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Torrent Pharmaceuticals Ltd.

Losar Shelcal Molnutor Alprax Ampoxin Arkamim Azulix Chymoral Dilzem Nebicard Nexpro Nikoran Regestrone Unienzyme Veloz Styptovit Finast Dynapress Regestrone Pregachieve

Index Presence

The company is present in 41Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year13.47%
3 Year12.82%
5 Year9.44%

Profit Growth

1 Year39.13%
3 Year23.95%
5 Year15%

ROE%

1 Year26.18%
3 Year21.01%
5 Year19.89%

ROCE %

1 Year27.82%
3 Year22.29%
5 Year20.02%

Debt/Equity

0.3354

Price to Cash Flow

55.96

Interest Cover Ratio

13.2314

CFO/PAT (5 Yr. Avg.)

1.78124849241265

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2026 68.31 0.00
Dec 2025 68.31 0.00
Sep 2025 68.31 0.00
Jun 2025 68.31 0.00
Mar 2025 68.31 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 23.9505119284958% for the Past 3 years.
  • Company has been maintaining healthy ROE of 21.0137666666667% over the past 3 years.
  • Company has been maintaining healthy ROCE of 22.2924666666667% over the past 3 years.
  • Company has a healthy Interest coverage ratio of 13.2314.
  • The Company has been maintaining an effective average operating margins of 32.9599046732205% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -11.2061 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.78124849241265.
  • The company has a high promoter holding of 68.31%.

 Limitations

  • The company has shown a poor revenue growth of 12.821350471942% for the Past 3 years.
  • The company is trading at a high PE of 65.52.
  • The company is trading at a high EV/EBITDA of 37.2398.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
Net Sales 2377 2433 2616 2762 2599
Total Expenditure 1490 1565 1637 1690 1599
Operating Profit 887 868 979 1072 1000
Other Income 3 15 -5 -27 -8
Interest 48 47 45 37 34
Depreciation 191 190 187 189 191
Exceptional Items 0 -24 0 -13 -10
Profit Before Tax 651 622 742 806 757
Tax 166 148 191 209 180
Profit After Tax 485 474 551 597 577
Adjusted EPS (Rs) 14.33 14 16.28 17.64 17.05

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 6450.57 6742.32 7695.2 8532.9 9682.44
Total Expenditure 4258.84 4641.6 5230.04 5643.73 6106.7
Operating Profit 2191.73 2100.72 2465.16 2889.17 3575.74
Other Income 118.34 204.21 81.88 91.49 31.53
Interest 334.12 236.29 297.68 303.04 213.4
Depreciation 609.84 602.43 672.34 761.05 759.48
Exceptional Items 0 0 0 0 -24.21
Profit Before Tax 1366.11 1466.21 1577.02 1916.57 2610.18
Tax 228.26 474.76 525.63 559.49 722.12
Net Profit 1137.85 991.45 1051.39 1357.08 1888.06
Adjusted EPS (Rs.) 33.62 29.29 31.06 40.1 55.78

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 84.62 84.62 169.23 169.23 169.23
Total Reserves 5945.48 6260.8 6286.73 6659.53 7423.27
Borrowings 2941.07 1971.6 2331.78 1603.78 1020.59
Other N/C liabilities 175.74 412.18 675.04 955.45 1249.04
Current liabilities 2585.8 2423.36 3409.15 2988.6 2979.63
Total Liabilities 11732.71 11152.56 12871.93 12376.59 12841.76
Assets
Net Block 6741.24 6251.25 7971.85 7985.92 7554.04
Capital WIP 554.84 543.54 674.9 203.94 365.59
Intangible WIP 33.27 23.96 23.03 22.29 36.25
Investments 174.87 183.66 205.12 322.27 410.52
Loans & Advances 75.61 65.3 68.42 95.24 121.45
Other N/C Assets 11 151.45 1.53 5.87 5.11
Current Assets 4141.88 3933.4 3927.08 3741.06 4348.8
Total Assets 11732.71 11152.56 12871.93 12376.59 12841.76
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 1366.11 1466.21 1577.02 1916.57 2610.18
Adjustment 884.8 827.91 990.49 957.61 969.5
Changes in Assets & Liabilities -468.12 86.25 -29.64 343.6 -515.07
Tax Paid -209.9 -240.27 -272.46 -324.68 -490.11
Operating Cash Flow 1572.89 2140.1 2265.41 2893.1 2574.5
Investing Cash Flow -316.28 -159.7 -2325.75 -296.07 -470.09
Financing Cash Flow -1581.2 -1977.27 80.74 -2577.57 -2104.46
Net Cash Flow -324.59 3.13 20.4 19.46 -0.05

Corporate Actions

Investors Details

PARTICULARS Mar 2025% Jun 2025% Sep 2025% Dec 2025% Mar 2026%
promoters 68.31 68.31 68.31 68.31 68.31
torrent investments limit... 68.31 68.31 68.31 68.31 68.31
PARTICULARS Mar 2025% Jun 2025% Sep 2025% Dec 2025% Mar 2026%
investors 31.69 31.69 31.69 31.69 31.69
hdfc mutual fund - hdfc p... - - 1.15 1.19 1.18
investor education and pr... 0.11 0.11 0.11 0.11 0.11
nps trust 1.80 1.89 2.09 2.44 2.49

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit ICRA
Credit ICRA
Credit ICRA
Credit FIFTCH
Credit ICRA
Credit ICRA
Credit ICRA
Credit FITCH
Credit ICRA
Credit FITCH
Credit FITCH
Credit ICRA
Credit FITCH
TYPE AGENCY Link
TYPE AGENCY Link
Research Geojit
Research BP Wealth
Research Way2wealth
Research HDFC Securities
Research BP Wealth
Research ICICI Securities Limited
Research Motilal Oswal
Research Reliance Securities
Research IDBI Capital

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY22
Concall Q3FY25
Concall Q3 FY20
Concall Q2FY21
Concall Q1FY24
Concall Q1FY21
Concall Q1FY20
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY21
Presentation Q2FY21

Company News

USFDA concludes inspection at Torrent Pharmaceuticals’ Bileshwarpura facility 13 Apr, 10:29 AM Torrent Pharmaceuticals launches Semaglutide brands in India 21 Mar, 6:00 PM Torrent Pharma - Quaterly Results 14 Feb, 12:00 AM Torrent Pharmaceuticals informs about board meeting 2 Feb, 10:35 AM Torrent Pharmaceuticals rises on acquiring stake in JB Chemicals 27 Jan, 9:56 AM Torrent Pharmaceuticals acquires stake in JB Chemicals 24 Jan, 12:45 PM Torrent Pharma moves up on getting nod to raise upto Rs 12,500 crore through NCDs 6 Jan, 2:38 PM Torrent Pharmaceuticals gets nod to raise upto Rs 12,500 crore through NCDs 6 Jan, 11:42 AM Torrent Pharmaceuticals informs about credit rating 3 Jan, 2:51 PM Torrent Pharmaceuticals zooms on reporting 30% rise in Q2 consolidated net profit 10 Nov, 2:55 PM Torrent Pharmaceuticals reports 30% rise in Q2 consolidated net profit 10 Nov, 2:41 PM Torrent Pharma - Quaterly Results 8 Nov, 12:00 AM torrent Pharmaceuticals informs about board meeting 27 Oct, 5:42 PM Torrent Pharmaceuticals informs about credit rating 7 Oct, 5:20 PM Torrent Pharmaceuticals informs about redemption of CP 18 Sep, 5:10 PM Torrent Pharmaceuticals enters into agreement to subscribe 26% stake in Torrent Urja 27 10 Sep, 5:22 PM Torrent Pharmaceuticals informs about disclosure 2 Aug, 4:56 PM Torrent Pharmaceuticals informs about financial results 28 Jul, 5:35 PM Torrent Pharmaceuticals reports 20% rise in Q1 consolidated net profit 28 Jul, 4:59 PM Torrent Pharma - Quaterly Results 28 Jul, 4:04 PM Torrent Pharma - Quaterly Results 28 Jul, 4:04 PM Torrent Pharma - Quaterly Results 28 Jul, 4:04 PM Torrent Pharmaceuticals seeks CCI’s nod to acquire majority stake in J B Chemicals 18 Jul, 2:12 PM Torrent Pharma executes SPA to acquire 2.41% stake in J.B. Chemicals & Pharmaceuticals 4 Jul, 10:40 AM Torrent Pharmaceuticals informs about teleconference 30 Jun, 10:02 AM Torrent Pharmaceuticals to acquire controlling stake in JB Pharma 30 Jun, 9:28 AM Torrent Pharmaceuticals raises Rs 300 crore through Commercial Papers 27 Jun, 11:30 AM Torrent Pharmaceuticals raises Rs 200 crore through Commercial Papers 21 Jun, 11:35 AM Torrent Pharma - Quaterly Results 20 May, 5:19 PM Torrent Pharma - Quaterly Results 20 May, 5:19 PM Torrent Pharma - Quaterly Results 20 May, 5:19 PM Torrent Pharmaceuticals informs about trading window closure 28 Mar, 5:29 PM Torrent Pharmaceuticals informs about outcome of board meeting 24 Jan, 5:21 PM Torrent Pharma - Quaterly Results 24 Jan, 4:45 PM Torrent Pharma - Quaterly Results 24 Jan, 4:45 PM Torrent Pharma - Quaterly Results 24 Jan, 4:45 PM Torrent Pharmaceuticals raises Rs 200 crore through commercial papers 27 Dec, 2:10 PM Torrent Pharma enters into agreement with Boehringer Ingelheim to acquire 3 anti-diabetes brands 5 Dec, 11:12 AM Torrent Pharma - Quaterly Results 25 Oct, 5:18 PM Torrent Pharma - Quaterly Results 25 Oct, 5:18 PM Torrent Pharma - Quaterly Results 25 Oct, 5:18 PM Torrent Pharmaceuticals incorporates Wholly owned subsidiary in Chile 27 Sep, 9:47 AM Torrent Pharmaceuticals raises Rs 200 crore through Commercial Papers 21 Sep, 2:27 PM Torrent Pharmaceuticals gets EIR with VAI classification for Gujarat manufacturing facility 30 Aug, 11:10 AM Torrent Pharmaceuticals informs about disclosure 30 Aug, 9:44 AM Torrent Pharmaceuticals informs about clarification 14 Aug, 12:54 PM Torrent Pharmaceuticals informs about change in management 13 Aug, 12:10 PM Torrent Pharmaceuticals reports 21% rise in Q1 consolidated net profit 24 Jul, 12:14 PM Torrent Pharma - Quaterly Results 23 Jul, 5:20 PM Torrent Pharma - Quaterly Results 23 Jul, 5:20 PM

Torrent Pharma Stock Price Analysis and Quick Research Report. Is Torrent Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Torrent Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Torrent Pharma has a PE ratio of 65.1265515941114 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Torrent Pharma has ROA of 14.9737% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Torrent Pharma has a Current ratio of 1.4595.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Torrent Pharma has a ROE of 26.1844%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Torrent Pharma has a Debt to Equity ratio of 0.3354 which means that the company has low proportion of debt in its capital.

  • Sales growth: Torrent Pharma has reported revenue growth of 13.4719% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Torrent Pharma for the current financial year is 36.930153969454%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Torrent Pharma is Rs 32 and the yield is 0.7576%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Torrent Pharma is Rs 64.9735. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Torrent Pharma in Ticker for free. Also, one can get the intrinsic value of Torrent Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Torrent Pharma FAQs

Q1. What is Torrent Pharma share price today?
Ans: The current share price of Torrent Pharma is Rs 4231.5.

Q2. What is the market capitalisation of Torrent Pharma?
Ans: Torrent Pharma has a market capitalisation of Rs 143213.187936 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Torrent Pharma?
Ans: The PE ratio of Torrent Pharma is 65.1265515941114 and the P/B ratio of Torrent Pharma is 15.855809000359, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Torrent Pharma share?
Ans: The 52-week high share price of Torrent Pharma is Rs 4482.9, and the 52-week low share price of Torrent Pharma is Rs 3101.6.

Q5. Does Torrent Pharma pay dividends?
Ans: Currently, Torrent Pharma pays dividends. Dividend yield of Torrent Pharma is around 0.7576%.

Q6. What are the face value and book value of Torrent Pharma shares?
Ans: The face value of Torrent Pharma shares is Rs 5, while the book value per share of Torrent Pharma is around Rs 266.8738. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Torrent Pharma?
Ans: Torrent Pharma has a total debt of Rs 2546.84 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Torrent Pharma?
Ans: The ROE of Torrent Pharma is 26.1844% and ROCE of Torrent Pharma is 27.8171%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Torrent Pharma a good buy for the long term?
Ans: The Torrent Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Torrent Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Torrent Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Torrent Pharma’s financials?
Ans: You can review Torrent Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Torrent Pharma

Torrent Pharma Share Price, Stock Analysis & Company Profile

Torrent Pharmaceuticals Limited (also referred to as Torrent Pharma) is a flagship company of the Torrent Group and a dominant player in the Indian Pharmaceuticals & Drugs Sector. Known for its strong presence in chronic therapeutic segments, the company has established itself as a leader in cardiovascular and central nervous system (CNS) therapies.

This page provides a comprehensive suite of tools for investors to track the Torrent Pharma share price, perform a detailed Torrent Pharmaceuticals stock analysis, and understand the company's growth in the global healthcare market.

About Torrent Pharmaceuticals Limited

Established in 1959 by Late Shri U. N. Mehta, Torrent Pharma is headquartered in Ahmedabad and has grown from a domestic firm into a global specialty pharmaceutical company. It operates in more than 40 countries, with significant market shares in India, Brazil, Germany, and the United States.

The company is distinguished by its focus on "Branded Generics" and its high R&D investment, which fuels its pipeline of complex formulations. Over the years, Torrent has successfully integrated major acquisitions, such as Unichem’s domestic business and Curatio Healthcare, to solidify its leadership in the Indian market.

Torrent Pharma Business Model

The company's business model is built on high-quality manufacturing and a focus on specialized therapy areas. Key operational pillars include:

  • Therapeutic Specialization: A leader in chronic therapies, including Cardiovascular (CV), Central Nervous System (CNS), Gastrointestinal (GI), and Vitamins Minerals Nutrients (VMN).

  • Global Branded Generics: Maintaining a strong front-end presence in regulated markets like Germany and Brazil, where it is among the top generic players.

  • Manufacturing Prowess: Operating state-of-the-art facilities across India and the US, many of which are approved by global regulatory bodies like the USFDA and EMA.

  • Research & Development: Investing significantly in its R&D centre to develop value-added medicines and new chemical entities.

  • Acquisition-Led Growth: A proven track record of acquiring and scaling brands to gain rapid entry into new therapeutic segments like dermatology and nephrology.

Torrent Pharma IPO and Listing Details

Torrent Pharma has been a long-standing wealth creator on the Indian stock exchanges, representing the steady growth of the domestic pharma industry.

  • Listing Year: 1972 (Public Issue)
  • IPO Price: Issued at a par value of Rs 100 during its initial capital raising in 1972.
  • Face Value: Rs 5 per share (Post-split).
  • ISIN: INE685A01028.
  • NSE Symbol: TORNTPHARM.
  • BSE Scrip Code: 500420.

Torrent Pharma Corporate Action History

The company has a consistent history of corporate actions designed to reward its shareholders and ensure liquidity in the market.

Bonus Share History

Torrent Pharma has issued bonus shares multiple times to reward long-term investors.

  • 2022: 1:1 Bonus Issue (1 bonus share for every 1 share held).
  • 2013: 1:1 Bonus Issue.
  • 2006: 1:1 Bonus Issue.

Stock Split History

The company has adjusted its face value in the past to improve accessibility for retail investors.

  • 2006: Stock split from a Face Value of Rs 10 to Rs 5.
  • Ex-Date: 20 February 2006.

Dividend History

The company is known for its regular dividend payouts, often declaring both interim and final dividends in a single financial year.

  • FY 2025-26: Declared an interim dividend of Rs 29.00 per share.

  • FY 2024-25: Total dividends included payouts of Rs 26.00 and Rs 6.00 per share.

  • FY 2023-24: Total dividends included payouts of Rs 22.00 and Rs 6.00 per share.

Investor Resources Available on This Page

Retail investors can access specialised data in the respective tables on this page to conduct a professional Torrent Pharma stock analysis:

  • Price Chart: Track the historical price action and long-term performance of the Torrent Pharmaceuticals share price. (data delayed by 15 minutes)

  • Company Ratios: Review critical metrics like P/E ratio, ROCE, Operating Profit Margin, and Debt-to-Equity.

  • Quarterly Results: Monitor the latest sales growth and net profit margins every quarter.

  • Balance Sheet: Analyse the company’s capital structure and its investment in manufacturing assets.

  • Cash Flow Statement: Evaluate how the company generates cash to fund its R&D and dividend payouts.

  • Shareholding & Promoters: Track the stake held by the Mehta family and the participation of institutional investors.

  • Pros & Cons: A simplified summary of the company’s brand strength in chronic therapies versus regulatory risks.

  • Annual Reports: Download official company reports to understand the management's vision for the future of global healthcare.

Frequently Asked Questions (FAQs)

Q1. What is the latest Torrent Pharma share price?
The updated price is displayed at the top of this page. Please note that all price data and charts are subject to a 15-minute delay from the exchanges.

Q2. Who are the promoters of Torrent Pharmaceuticals?
The company is promoted by the Torrent Group, led by the Mehta family (Mr. Samir Mehta and Mr. Sudhir Mehta).

Q3. When was the last bonus issue for Torrent Pharma?
The most recent bonus issue took place in July 2022, where the company issued shares in a 1:1 ratio.

Q4. Does Torrent Pharma pay regular dividends?
Yes, the company has a strong track record of paying regular dividends. It typically declares an interim dividend in the second half of the financial year and a final dividend after the annual results.

Q5. Has Torrent Pharma ever split its shares?
Yes, the company last split its shares in February 2006, reducing the face value from Rs 10 to Rs 5 per share.

Q6. Where can I find the quarterly results for Torrent Pharma?
All quarterly financial statements, including consolidated revenue and EBITDA, are available in the "Quarterly Results" section on this page.

Q7. How can I download the Torrent Pharma Annual Report?
The latest and past Annual Reports can be accessed directly from the "Reports" or "Documents" section table provided on this page.

Read More
X